Safety, Tolerability, and Pharmacokinetics of a Novel Human Hepatitis B Virus Capsid Assembly Modulator Canocapavir: A Randomized First-in-Human Study-Reference-Cited by-同舟云学术

Safety, Tolerability, and Pharmacokinetics of a Novel Human Hepatitis B Virus Capsid Assembly Modulator Canocapavir: A Randomized First-in-Human Study

Published:2023 Issue:4 Volume:2 Page:524-531
ISSN:2772-5723
Container-title:Gastro Hep Advances
language:en
Short-container-title:Gastro Hep Advances

Author:

Jiang Xiuhong,Hua Bo,Liu Gang,Xia Tian,Deng Aiyun,Lu Hui,Guo Ruoling,Wang Zhe,Liang Bo,Chen Huanming,Jin Qiu,Zhang Zhijun^ORCID

Publisher

Elsevier BV

Reference7 articles.

1. Therapeutic strategies for hepatitis B virus infection: towards a cure;Fanning;Nat Rev Drug Discov,2019

2. Pegylated interferon alfa for chronic hepatitis B: systematic review and meta-analysis;Kim;J Viral Hepat,2016

3. Targets and future direct-acting antiviral approaches to achieve hepatitis B virus cure;Asselah;Lancet Gastroenterol Hepatol,2019

4. Targeting the multifunctional HBV core protein as a potential cure for chronic hepatitis B;Viswanathan;Antiviral Res,2020

5. Role of core/capsid inhibitors in functional cure strategies for chronic hepatitis B;Hui;Curr Hepatol Rep,2020

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety, tolerability, pharmacokinetics, and antiviral activity of the novel core protein allosteric modulator ZM-H1505R (Canocapavir) in chronic hepatitis B patients: a randomized multiple-dose escalation trial;BMC Medicine;2023-03-16

2. The progress of molecules and strategies for the treatment of HBV infection;Frontiers in Cellular and Infection Microbiology;2023-03-15

3. Future of Chronic Hepatitis B Infection Therapies;Gastro Hep Advances;2023